CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: MED13 (ImmuneEditome ID:9969)

1. Gene summary of enriched editing regions for MED13

check button Gene summary
Gene informationGene symbol

MED13

Gene ID

9969

GeneSynonymsARC250|DRIP250|HSPC221|MRD61|THRAP1|TRAP240
GeneCytomap

17q23.2

GeneTypeprotein-coding
GeneDescriptionmediator of RNA polymerase II transcription subunit 13|activator-recruited cofactor 250 kDa component|mediator of RNA polymerase II transcription, subunit 13 homolog|thyroid hormone receptor-associated protein 1|thyroid hormone receptor-associated protein complex 240 kDa component|thyroid hormone receptor-associated protein complex component TRAP240|thyroid hormone receptor-associated protein, 240 kDa subunit|vitamin D3 receptor-interacting protein complex component DRIP250
GeneModificationdate20230329
UniprotIDQ9UHV7
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr17:61954858-61955304:-ENST00000397786.5ENSG00000108510.8MED13intronicMLT1Dchr17:61954858-61955304:-.alignment
chr17:61979412-61980017:-ENST00000397786.5ENSG00000108510.8MED13intronicAluSz6,AluSx3,L2achr17:61979412-61980017:-.alignment
chr17:61981111-61981343:-ENST00000397786.5ENSG00000108510.8MED13intronicL2a,AluSqchr17:61981111-61981343:-.alignment
chr17:61990236-61992031:-ENST00000397786.5ENSG00000108510.8MED13intronic(AT)n,AluSc,AluSz,L1MA8,MIR3,L2b,AluSx1chr17:61990236-61992031:-.alignment
chr17:61998582-62001083:-ENST00000397786.5ENSG00000108510.8MED13intronic(T)n,AluJr,AluJb,AluSx3chr17:61998582-62001083:-.alignment
chr17:62010024-62010226:-ENST00000397786.5ENSG00000108510.8MED13intronicAluSzchr17:62010024-62010226:-.alignment
chr17:62019833-62020695:-ENST00000397786.5ENSG00000108510.8MED13intronicL1ME3,AluSc,AluY,SVA_Dchr17:62019833-62020695:-.alignment
chr17:62019833-62020695:-ENST00000583958.1ENSG00000108510.8MED13intronicL1ME3,AluSc,AluY,SVA_Dchr17:62019833-62020695:-.alignment
chr17:62021915-62022975:-ENST00000397786.5ENSG00000108510.8MED13intronicL1ME3G,AluJr4,AluSz6,FLAM_C,L2achr17:62021915-62022975:-.alignment
chr17:62021915-62022975:-ENST00000583958.1ENSG00000108510.8MED13intronicL1ME3G,AluJr4,AluSz6,FLAM_C,L2achr17:62021915-62022975:-.alignment
chr17:62024054-62025071:-ENST00000397786.5ENSG00000108510.8MED13intronicL1PREC2,AluSxchr17:62024054-62025071:-.alignment
chr17:62024054-62025071:-ENST00000583958.1ENSG00000108510.8MED13intronicL1PREC2,AluSxchr17:62024054-62025071:-.alignment
chr17:62039372-62039840:-ENST00000397786.5ENSG00000108510.8MED13intronicAluSq2,AluSx1chr17:62039372-62039840:-.alignment
chr17:62041635-62041904:-ENST00000397786.5ENSG00000108510.8MED13intronicAluJochr17:62041635-62041904:-.alignment
chr17:62046743-62047334:-ENST00000397786.5ENSG00000108510.8MED13intronicAluJb,AluJr,L1PA8,AluSx1chr17:62046743-62047334:-.alignment
chr17:62060017-62061020:-ENST00000397786.5ENSG00000108510.8MED13intronicAluSx,AluY,AluSc8chr17:62060017-62061020:-.alignment


Top

2. Tumor-specific enriched editing regions for MED13


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr17:62039372-62039840:-OVEER4.8210e-032.8577e-025.1701e+03image

Top

3. Enriched editing regions and immune related genes for MED13


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr17:61998582-62001083:-ESCAEERENSG00000259556,RP11-56B16.2-0.49481.4439e-067.5314e-09-0.4461imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MTORC1_SIGNALING
chr17:61998582-62001083:-ESCAEERENSG00000200651,Y_RNA-0.47734.9233e-061.1765e-07-0.4124imageNNNAB_cells_naiveGSVA_HALLMARK_SPERMATOGENESIS
chr17:61998582-62001083:-ESCAEERENSG00000250461,RP11-631M6.2-0.46361.1746e-054.7795e-08-0.4238imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr17:61998582-62001083:-ESCAEERENSG00000269688,AC008982.2-0.46241.5097e-059.6340e-09-0.4432imageNNNAB_cells_naiveGSVA_HALLMARK_GLYCOLYSIS
chr17:61998582-62001083:-ESCAEERENSG00000200953,Y_RNA-0.45741.5439e-059.6056e-09-0.4432imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_GLYCOLYSIS
chr17:61998582-62001083:-ESCAEERENSG00000279078,SND1-IT1-0.46811.6467e-052.3770e-08-0.4324imageNNNAB_cells_naiveGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr17:61998582-62001083:-ESCAEERENSG00000257246,RP11-416A17.6-0.45422.2835e-053.5999e-08-0.4274imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_P53_PATHWAY
chr17:61998582-62001083:-ESCAEERENSG00000065833,ME10.30881.2363e-021.0781e-090.4678imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr17:61998582-62001083:-ESCAEERENSG00000111907,TPD52L10.30591.4345e-024.8877e-090.4510imageNNTPD52L1T_cells_CD4_memory_restingGSVA_HALLMARK_KRAS_SIGNALING_DN
chr17:61998582-62001083:-ESCAEERENSG00000146373,RNF2170.28462.4100e-029.2976e-080.4154imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PANCREAS_BETA_CELLS

More results



Top

4. Enriched editing regions and immune related splicing for MED13


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr17:61998582-62001083:-
ESCAEERIRENSG00000198911.7chr2241898648:41898781:41899236:41899553-0.28724.2157e-024.3857e-07-0.4352imageNNSREBF2Macrophages_M2GSVA_HALLMARK_HYPOXIA
chr17:61998582-62001083:-
ESCAEERIRENSG00000111725.6chr12119671494:119671668:119672300:119672427-0.36413.0196e-031.3948e-06-0.4115imageNNPRKAB1T_cells_CD4_memory_restingGSVA_HALLMARK_MTORC1_SIGNALING
chr17:61998582-62001083:-
ESCAEERIRENSG00000116350.11chr129165889:29166912:29168502:29168638-0.40282.2269e-034.9247e-08-0.4287imageNNNAMacrophages_M2GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
ENSG00000108510.8,MED13
ESCAEAGIRENSG00000174720.11chr4112646790:112647127:112647198:112647449-0.42827.0891e-041.6496e-08-0.4342imageNACIN1;ADAR;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;RBM22;RBM47;RNF219;SAFB2;SF3A3;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZFP36;ZNF184NADendritic_cells_activatedGSVA_HALLMARK_MTORC1_SIGNALING
chr17:61998582-62001083:-
ESCAEERIRENSG00000166888.6chr1257102828:57102921:57104326:57104586-0.37527.1680e-038.7229e-09-0.4444imageNNSTAT6T_cells_regulatory_(Tregs)GSVA_HALLMARK_MTORC1_SIGNALING
chr17:61998582-62001083:-
ESCAEERIRENSG00000140463.9chr1572735076:72735966:72736761:72736963-0.43634.3808e-043.0525e-07-0.4035imageNNBBS4Macrophages_M2GSVA_HALLMARK_GLYCOLYSIS
ENSG00000108510.8,MED13
ESCAEAGIRENSG00000188811.8chr1339039135:39039711:39044089:39044181-0.36095.3951e-031.7933e-07-0.4296imageNAIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZC3H7B;ZNF184NAB_cells_naiveGSVA_HALLMARK_GLYCOLYSIS
chr17:61998582-62001083:-
ESCAEERIRENSG00000089053.8chr12121309700:121309863:121309969:121310011-0.42418.3459e-041.0238e-09-0.4712imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_MTORC1_SIGNALING
chr17:61998582-62001083:-
ESCAEERIRENSG00000204859.7chr16580540:6582299:6585918:6586030-0.44633.0343e-045.5477e-08-0.4233imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_GLYCOLYSIS
chr17:61998582-62001083:-
ESCAEERIRENSG00000188811.8chr1339039135:39039711:39044089:39044181-0.39071.2840e-032.9071e-08-0.4567imageNNNAB_cells_naiveGSVA_HALLMARK_GLYCOLYSIS

More results



Top

5. Enriched editing regions and immune infiltration for MED13


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr17:61998582-62001083:-BLCAEERT_cells_CD4_memory_resting1.8862e-02-0.2801image
ENSG00000108510.8,MED13BLCAEAGT_cells_CD4_memory_resting4.3294e-02-0.2389image
chr17:61998582-62001083:-BRCAEERT_cells_gamma_delta2.8479e-02-0.1886image
chr17:61998582-62001083:-CESCEERMacrophages_M19.5067e-03-0.4264image
ENSG00000108510.8,MED13CESCEAGMacrophages_M18.1810e-03-0.4283image
chr17:61998582-62001083:-COADEERMacrophages_M22.8784e-02-0.3336image
ENSG00000108510.8,MED13COADEAGT_cells_follicular_helper4.4450e-020.2978image
chr17:61998582-62001083:-ESCAEERDendritic_cells_resting5.6234e-030.2229image
chr17:62019833-62020695:-ESCAEERPlasma_cells4.9077e-020.3132image
chr17:62024054-62025071:-ESCAEERNK_cells_activated3.0310e-020.4731image
ENSG00000108510.8,MED13ESCAEAGDendritic_cells_resting4.2596e-030.2284image
ENSG00000108510.8,MED13GBMEAGPlasma_cells3.3632e-030.4757image
chr17:61998582-62001083:-KIRCEERB_cells_memory3.0678e-02-0.3511image
ENSG00000108510.8,MED13KIRCEAGB_cells_memory2.5985e-02-0.3394image
chr17:61990236-61992031:-LAMLEERDendritic_cells_activated4.7038e-02-0.2400image
chr17:62041635-62041904:-LAMLEERT_cells_CD4_naive3.0623e-02-0.4419image
chr17:61998582-62001083:-LUADEEREosinophils4.6758e-03-0.2254image
chr17:61998582-62001083:-LUSCEERT_cells_gamma_delta1.6467e-020.2780image
ENSG00000108510.8,MED13LUSCEAGT_cells_gamma_delta2.0129e-020.2627image
chr17:61998582-62001083:-SARCEERMacrophages_M21.9186e-020.5184image
ENSG00000108510.8,MED13SARCEAGMacrophages_M21.9186e-020.5184image
chr17:61990236-61992031:-STADEERNK_cells_activated1.0291e-020.4282image
chr17:61998582-62001083:-STADEERMacrophages_M23.6617e-030.1806image
chr17:62019833-62020695:-STADEERT_cells_CD4_memory_resting4.0904e-020.2468image
chr17:62024054-62025071:-STADEERMacrophages_M01.0164e-02-0.3501image
chr17:62039372-62039840:-STADEERT_cells_CD82.2786e-030.3693image
ENSG00000108510.8,MED13STADEAGMacrophages_M29.8809e-030.1545image
chr17:61998582-62001083:-THCAEERMacrophages_M24.5666e-03-0.1587image
ENSG00000108510.8,MED13THCAEAGMacrophages_M25.0656e-03-0.1561image
chr17:61998582-62001083:-UCECEERMonocytes5.2607e-030.5619image
ENSG00000108510.8,MED13UCECEAGB_cells_memory4.5462e-020.3881image


Top

6. Enriched editing regions and immune gene sets for MED13


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr17:61998582-62001083:-STADEER4.7549e-050.25092.2123e-030.19019.1152e-040.20571.6670e-040.2327image
ENSG00000108510.8,MED13STADEAG7.3481e-030.16042.3419e-020.13593.4634e-020.12681.7903e-050.2542image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000108510.8,MED13BLCAGSVA_HALLMARK_MTORC1_SIGNALINGEAG2.7972e-020.2591image
chr17:61998582-62001083:-BLCAGSVA_HALLMARK_GLYCOLYSISEER1.3712e-020.2934image
ENSG00000108510.8,MED13BRCAGSVA_HALLMARK_ANGIOGENESISEAG2.8781e-050.3302image
chr17:61998582-62001083:-BRCAGSVA_HALLMARK_ANGIOGENESISEER3.9782e-050.3459image
chr17:61998582-62001083:-COADGSVA_HALLMARK_KRAS_SIGNALING_DNEER1.4912e-030.4695image
ENSG00000108510.8,MED13COADGSVA_HALLMARK_HYPOXIAEAG5.3750e-040.4906image
chr17:62024054-62025071:-ESCAGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER2.5073e-020.4872image
chr17:61998582-62001083:-ESCAGSVA_HALLMARK_GLYCOLYSISEER6.9237e-050.3160image
chr17:62019833-62020695:-ESCAGSVA_HALLMARK_PANCREAS_BETA_CELLSEER1.0886e-020.3984image
chr17:62039372-62039840:-ESCAGSVA_HALLMARK_MITOTIC_SPINDLEEER6.9837e-03-0.4746image
ENSG00000108510.8,MED13ESCAGSVA_HALLMARK_SPERMATOGENESISEAG2.1895e-040.2927image
chr17:61998582-62001083:-KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER9.6576e-030.4146image
ENSG00000108510.8,MED13KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG7.3464e-030.4032image
chr17:62041635-62041904:-LAMLGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.2885e-020.4998image
chr17:61998582-62001083:-LAMLGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER9.0785e-050.3743image
chr17:61990236-61992031:-LAMLGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER2.7224e-020.2659image
ENSG00000108510.8,MED13LAMLGSVA_HALLMARK_PROTEIN_SECRETIONEAG7.4265e-030.2347image
chr17:61998582-62001083:-LGGGSVA_HALLMARK_UV_RESPONSE_DNEER1.4267e-040.4176image
ENSG00000108510.8,MED13LGGGSVA_HALLMARK_UV_RESPONSE_DNEAG1.4267e-040.4176image
chr17:61998582-62001083:-LIHCGSVA_HALLMARK_ADIPOGENESISEER3.8840e-020.4156image
ENSG00000108510.8,MED13LIHCGSVA_HALLMARK_ADIPOGENESISEAG3.6116e-020.4210image
ENSG00000108510.8,MED13LUADGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG4.2846e-040.2687image
chr17:61998582-62001083:-LUADGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER7.7620e-050.3110image
chr17:61998582-62001083:-OVGSVA_HALLMARK_PROTEIN_SECRETIONEER6.2052e-040.2694image
ENSG00000108510.8,MED13OVGSVA_HALLMARK_PROTEIN_SECRETIONEAG4.3331e-040.2725image
ENSG00000108510.8,MED13PRADGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.3965e-020.3390image
chr17:61998582-62001083:-SARCGSVA_HALLMARK_TGF_BETA_SIGNALINGEER4.1515e-02-0.4595image
ENSG00000108510.8,MED13SARCGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG4.1515e-02-0.4595image
ENSG00000108510.8,MED13STADGSVA_HALLMARK_UV_RESPONSE_UPEAG3.9944e-070.2984image
chr17:62019833-62020695:-STADGSVA_HALLMARK_ANGIOGENESISEER2.1322e-02-0.2768image
chr17:62039372-62039840:-STADGSVA_HALLMARK_HYPOXIAEER9.2832e-040.3982image
chr17:62024054-62025071:-STADGSVA_HALLMARK_KRAS_SIGNALING_DNEER3.1663e-020.2956image
chr17:61998582-62001083:-STADGSVA_HALLMARK_UV_RESPONSE_UPEER1.6291e-070.3196image
chr17:62046743-62047334:-STADGSVA_HALLMARK_PANCREAS_BETA_CELLSEER1.8337e-020.3760image
chr17:61998582-62001083:-TGCTGSVA_HALLMARK_APICAL_SURFACEEER1.4442e-020.3406image
ENSG00000108510.8,MED13TGCTGSVA_HALLMARK_APICAL_SURFACEEAG7.1788e-030.3651image
ENSG00000108510.8,MED13THCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.7001e-030.1669image
chr17:61998582-62001083:-THCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.9077e-030.1734image
chr17:61998582-62001083:-UCECGSVA_HALLMARK_KRAS_SIGNALING_DNEER1.0844e-020.5208image
ENSG00000108510.8,MED13UCECGSVA_HALLMARK_KRAS_SIGNALING_DNEAG1.4659e-020.4645image


Top

7. Enriched editing regions and drugs for MED13


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000108510.8,MED13BLCALFM.A13EAG5.7860e-030.3222image
chr17:61998582-62001083:-BLCALFM.A13EER4.9383e-030.3324image
ENSG00000108510.8,MED13BRCAATRAEAG6.2427e-030.2195image
chr17:61998582-62001083:-BRCAATRAEER7.2228e-030.2302image
chr17:61998582-62001083:-COADBexaroteneEER1.8282e-02-0.3584image
ENSG00000108510.8,MED13COADABT.263EAG1.9138e-020.3443image
chr17:62024054-62025071:-ESCAAZD8055EER6.6995e-03-0.5724image
chr17:61998582-62001083:-ESCADocetaxelEER1.0651e-04-0.3082image
chr17:62019833-62020695:-ESCAImatinibEER3.2587e-040.5397image
chr17:62039372-62039840:-ESCAElesclomolEER1.6360e-03-0.5420image
ENSG00000108510.8,MED13ESCADocetaxelEAG1.7487e-04-0.2970image
ENSG00000108510.8,MED13GBMMidostaurinEAG1.7038e-020.3952image
ENSG00000108510.8,MED13KIRCEmbelinEAG4.1244e-02-0.3126image
chr17:61998582-62001083:-KIRCEmbelinEER8.6348e-03-0.4201image
chr17:62041635-62041904:-LAMLCisplatinEER9.8518e-030.5160image
chr17:61990236-61992031:-LAMLLenalidomideEER1.2760e-020.2984image
chr17:61998582-62001083:-LAMLCisplatinEER1.3043e-020.2427image
ENSG00000108510.8,MED13LGGGW843682XEAG1.1870e-030.3605image
chr17:61998582-62001083:-LGGGW843682XEER1.1870e-030.3605image
ENSG00000108510.8,MED13LIHCGefitinibEAG9.3406e-03-0.5091image
chr17:61998582-62001083:-LIHCBMS.708163EER6.7389e-03-0.5274image
ENSG00000108510.8,MED13LUADDocetaxelEAG9.7926e-04-0.2521image
chr17:61998582-62001083:-LUADDocetaxelEER3.3653e-03-0.2334image
chr17:61998582-62001083:-LUSCCEP.701EER1.6558e-03-0.3595image
ENSG00000108510.8,MED13LUSCCEP.701EAG4.0950e-03-0.3216image
ENSG00000108510.8,MED13PRADATRAEAG2.5128e-020.3104image
ENSG00000108510.8,MED13SARCEHT.1864EAG1.5967e-02-0.5311image
chr17:61998582-62001083:-SARCEHT.1864EER1.5967e-02-0.5311image
ENSG00000108510.8,MED13SKCMA.770041EAG4.2040e-020.4015image
chr17:62039372-62039840:-STADBortezomibEER3.4266e-02-0.2610image
chr17:61990236-61992031:-STADBryostatin.1EER3.2890e-02-0.3615image
chr17:62019833-62020695:-STADCamptothecinEER3.9668e-020.2483image
chr17:61998582-62001083:-STADBMS.708163EER3.8603e-030.1796image
chr17:62046743-62047334:-STADBortezomibEER1.0137e-02-0.4070image
ENSG00000108510.8,MED13STADBMS.708163EAG4.9816e-040.2075image
ENSG00000108510.8,MED13TGCTAS601245EAG4.6384e-02-0.2749image
ENSG00000108510.8,MED13THCAAICAREAG1.0437e-04-0.2149image
chr17:61998582-62001083:-THCAAICAREER6.9968e-05-0.2211image
chr17:61998582-62001083:-UCECAZD7762EER7.7908e-03-0.5402image
ENSG00000108510.8,MED13UCECAZD7762EAG3.5194e-03-0.5417image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType